Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-05-31FDA Approved: LACOSAMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' original application for lacosamide, enabling a generic lacosamide product to enter the market.
-
FDA label_change · 2022-05-25FDA Approved: ZONISAMIDE — Supplemental Application (Viona Pharmaceuticals Inc)
The FDA approved a supplemental application for Zonisamide from Viona Pharmaceuticals Inc, resulting in changes to the product label.
-
FDA approval · 2022-05-19FDA Approved: LACOSAMIDE ORAL SOLUTION — Original Application (Ascend Laboratories, LLC)
The FDA approved an ANDA for lacosamide oral solution from Ascend Laboratories, LLC. This generic formulation is intended for use in treatin…
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures [Phase 4]
Phase 4 trial evaluating perampanel as monotherapy or first adjunctive therapy for various seizure types in partial onset and generalized se…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures [Phase 2]
Phase 2 double-blind, randomized, placebo-controlled trial evaluating YKP3089 as adjunctive therapy for partial onset seizures; results were…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-04-07FDA Approved: LACOSAMIDE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' original application for lacosamide (generic), enabling marketing of a generic lacosamide product for s…
-
FDA approval · 2022-03-31FDA Approved: LACOSAMIDE — Original Application (Ascend Laboratories, LLC)
FDA approved lacosamide as a generic product from Ascend Laboratories under an Original Application (ANDA 214695). Lacosamide is indicated f…
-
FDA approval · 2022-03-28FDA Approved: LEVETIRACETAM — Original Application (Solco Healthcare US, LLC)
FDA approves Solco Healthcare US, LLC's generic levetiracetam through an Original Application (ANDA). The approval covers the same epilepsy …
-
FDA approval · 2022-03-22FDA Approved: PREGABALIN — Original Application (Advagen Pharma Ltd.)
FDA approved Pregabalin under an Original Application for Advagen Pharma Ltd., authorizing the generic product.
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's Original Application for a generic lacosamide product, enabling its marketing as an anticonvulsant for par…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved the original application (ANDA) for lacosamide as a generic product by Alembic Pharmaceuticals Inc., enabling its marketing as …
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (ScieGen Pharmaceuticals Inc)
FDA approved ScieGen Pharmaceuticals Inc's lacosamide generic under an Original Application (ANDA205237) for marketing in epilepsy patients.…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (MSN LABORATORIES PRIVATE LIMITED)
FDA approved MSN Laboratories' original application for lacosamide as a generic anticonvulsant under an ANDA, expanding access to lacosamide…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Glenmark Pharmaceuticals Inc. USA)
The FDA approved Glenmark’s lacosamide as an original generic drug application (ANDA); lacosamide is an anticonvulsant used to treat partial…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Tris Pharma Inc)
FDA approved lacosamide from Tris Pharma Inc as an original generic drug application (ANDA 208308).
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved lacosamide as an original application (ANDA) for Amneal Pharmaceuticals of New York LLC, making a generic lacosamide available …
-
FDA approval · 2022-03-08FDA Approved: PREGABALIN — Original Application (Eskayef Pharmaceuticals Limited)
FDA approved Eskayef Pharmaceuticals Limited's original application for generic pregabalin (ANDA212988).
-
FDA approval · 2022-02-18FDA Approved: PREGABALIN — Original Application (Patrin Pharma, Inc.)
FDA approved an original application for pregabalin from Patrin Pharma, making a generic version available. This marks the approval of a gen…
-
FDA approval · 2022-01-11FDA Approved: OXCARBAZEPINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for oxcarbazepine, a generic anticonvulsant indicated for partial seizures.
-
FDA approval · 2021-10-14FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., to expand its approved indications for epilepsy.
-
FDA label_change · 2021-09-20FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc. The approval results in a labeling change to the product …
-
FDA approval · 2021-09-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Vimpat (lacosamide) by UCB, Inc.
-
FDA approval · 2021-09-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The approval pertains to changes to the drug's la…
-
FDA approval · 2021-09-02FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for BRIVIACT (brivaracetam) filed by UCB, Inc. The approval confirms modifications to the drug's lab…
-
FDA approval · 2021-08-27FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc. The approval updates Briviact's labeling and/…